Literature DB >> 22147974

Liver transplantation for hepatocellular carcinoma on cirrhosis: strategies to avoid tumor recurrence.

Marco Vivarelli, Andrea Risaliti.   

Abstract

Hepatocellular carcinoma (HCC) is one of the most frequent neoplasms worldwide and in most cases it is associated with chronic liver disease. Liver transplantation (LT) is potentially the optimal treatment for those patients with HCC who have a poor functional hepatic reserve due to their underlying chronic liver disease. However, due to the limited availability of donors, only those patients whose oncologic profile is favorable can be considered for LT. Despite the careful selection of candidates based on strict rules, 10 to 20% of liver transplant recipients who have HCC in the native cirrhotic liver develop tumor recurrence after transplantation. The selection criteria presently employed to minimize the risk of recurrence are based on gross tumor characteristics defined by imaging techniques; unfortunately, the accuracy of imaging is far from being optimal. Furthermore, microscopic tumor features that are strictly linked with prognosis can not be assessed prior to transplantation. Pre-transplantation tumor downstaging may allow transplantation in patients initially outside the selection criteria and seems to improve the prognosis; it also provides information on tumor biology. The main peculiarity of the transplantation setting, when this is compared with other modalities of treatment, is the need for pharmacological immunosuppression: this is based on drugs that have been demonstrated to increase the risk of tumor development. As HCC is an aggressive malignancy, immunosuppression has to be handled carefully in patients who have HCC at the time of transplantation and new categories of immunosuppressive agents should be considered. Adjuvant chemotherapy following transplantation has failed to show any significant advantage. The aim of the present study is to review the possible strategies to avoid recurrence of HCC after liver transplantation based on the current clinical evidence and the more recent developments and to discuss possible future directions.

Entities:  

Keywords:  Chemotherapy; Hepatocellular carcinoma; Immunosuppression; Liver transplantation; Tumor recurrence

Mesh:

Substances:

Year:  2011        PMID: 22147974      PMCID: PMC3229622          DOI: 10.3748/wjg.v17.i43.4741

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  59 in total

1.  Effect of systemic cyclosporine on tumor recurrence after liver transplantation in a model of hepatocellular carcinoma.

Authors:  C E Freise; L Ferrell; T Liu; N L Ascher; J P Roberts
Journal:  Transplantation       Date:  1999-02-27       Impact factor: 4.939

2.  Response to transarterial chemoembolization as a biological selection criterion for liver transplantation in hepatocellular carcinoma.

Authors:  Gerd Otto; Sascha Herber; Michael Heise; Ansgar W Lohse; Christian Mönch; Fernando Bittinger; Maria Hoppe-Lotichius; Marcus Schuchmann; Anja Victor; Michael Pitton
Journal:  Liver Transpl       Date:  2006-08       Impact factor: 5.799

3.  Effect of long-term immunosuppression in kidney-graft recipients on cancer incidence: randomised comparison of two cyclosporin regimens.

Authors:  J Dantal; M Hourmant; D Cantarovich; M Giral; G Blancho; B Dreno; J P Soulillou
Journal:  Lancet       Date:  1998-02-28       Impact factor: 79.321

Review 4.  Advanced hepatocellular carcinoma. Review of targeted molecular drugs.

Authors:  Rogério Camargo Pinheiro Alves; Daniele Alves; Betty Guz; Carla Matos; Monica Viana; Michele Harriz; Deborah Terrabuio; Mario Kondo; Otavio Gampel; Paula Polletti
Journal:  Ann Hepatol       Date:  2011 Jan-Mar       Impact factor: 2.400

5.  Accelerated growth rates of recurrent hepatocellular carcinoma after liver transplantation.

Authors:  I Yokoyama; B Carr; H Saitsu; S Iwatsuki; T E Starzl
Journal:  Cancer       Date:  1991-11-15       Impact factor: 6.860

6.  Surgical treatment of hepatocellular carcinoma: experience with liver resection and transplantation in 198 patients.

Authors:  B Ringe; R Pichlmayr; C Wittekind; G Tusch
Journal:  World J Surg       Date:  1991 Mar-Apr       Impact factor: 3.352

7.  Liver transplantation for malignant disease. Results in 93 consecutive patients.

Authors:  J G O'Grady; R J Polson; K Rolles; R Y Calne; R Williams
Journal:  Ann Surg       Date:  1988-04       Impact factor: 12.969

8.  Role of liver transplantation in cancer therapy.

Authors:  S Iwatsuki; R D Gordon; B W Shaw; T E Starzl
Journal:  Ann Surg       Date:  1985-10       Impact factor: 12.969

Review 9.  Adjuvant chemotherapy improves survival after liver transplantation for hepatocellular carcinoma.

Authors:  K M Olthoff; M H Rosove; C R Shackleton; D K Imagawa; D G Farmer; P Northcross; A L Pakrasi; P Martin; L I Goldstein; A Shaked
Journal:  Ann Surg       Date:  1995-06       Impact factor: 12.969

10.  Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis.

Authors:  V Mazzaferro; E Regalia; R Doci; S Andreola; A Pulvirenti; F Bozzetti; F Montalto; M Ammatuna; A Morabito; L Gennari
Journal:  N Engl J Med       Date:  1996-03-14       Impact factor: 176.079

View more
  7 in total

1.  Chronic bile duct hyperplasia is a chronic graft dysfunction following liver transplantation.

Authors:  Jian-Wen Jiang; Zhi-Gang Ren; Guang-Ying Cui; Zhao Zhang; Hai-Yang Xie; Lin Zhou
Journal:  World J Gastroenterol       Date:  2012-03-14       Impact factor: 5.742

Review 2.  Diagnostic and therapeutic management of hepatocellular carcinoma.

Authors:  Francesco Bellissimo; Marilia Rita Pinzone; Bruno Cacopardo; Giuseppe Nunnari
Journal:  World J Gastroenterol       Date:  2015-11-14       Impact factor: 5.742

Review 3.  Liver transplantation for hepatocellular carcinoma.

Authors:  Jerome Byam; John Renz; J Michael Millis
Journal:  Hepatobiliary Surg Nutr       Date:  2013-02       Impact factor: 7.293

4.  Doxorubicin-eluting bead vs conventional transcatheter arterial chemoembolization for hepatocellular carcinoma before liver transplantation.

Authors:  Daniele Nicolini; Gianluca Svegliati-Baroni; Roberto Candelari; Cinzia Mincarelli; Alessandra Mandolesi; Italo Bearzi; Federico Mocchegiani; Andrea Vecchi; Roberto Montalti; Antonio Benedetti; Andrea Risaliti; Marco Vivarelli
Journal:  World J Gastroenterol       Date:  2013-09-14       Impact factor: 5.742

Review 5.  Hierarchical and selective roles of galectins in hepatocarcinogenesis, liver fibrosis and inflammation of hepatocellular carcinoma.

Authors:  María L Bacigalupo; Malena Manzi; Gabriel A Rabinovich; María F Troncoso
Journal:  World J Gastroenterol       Date:  2013-12-21       Impact factor: 5.742

Review 6.  Contribution of galectin-1, a glycan-binding protein, to gastrointestinal tumor progression.

Authors:  María L Bacigalupo; Pablo Carabias; María F Troncoso
Journal:  World J Gastroenterol       Date:  2017-08-07       Impact factor: 5.742

Review 7.  Use of Mass Spectrometry to Screen Glycan Early Markers in Hepatocellular Carcinoma.

Authors:  Raphaela Menezes de Oliveira; Carlos Andre Ornelas Ricart; Aline Maria Araujo Martins
Journal:  Front Oncol       Date:  2018-01-15       Impact factor: 6.244

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.